Life sciences exits involve some of the most difficult and creative deal negotiations. Transactions that are largely reliant on contingent consideration paid out after the deal closes have become the norm for life sciences M&A deals. Deal negotiation and post-closing management can powerfully impact investor and client returns on deals where earn-outs comprise the substantial portion of potential consideration.
Please join us for a unique discussion of life sciences M&A that will highlight trends in deal terms, returns, and earn-out milestones and achievement rates based on data and analysis from SRS's recently released 2012 SRS Life Sciences M&A Study.
Click here to register.
- Analysis of life sciences exits, including time-to-exit, contingent payouts, and investor returns
- Earn-out milestone achievement rates, and why they are missed
- Tips for negotiating life sciences M&A
- Post-closing best practices for managing relationships with the acquirer
and investigation of missed milestones
Bruce Booth Partner, Atlas Venture
Bruce joined Atlas Venture in 2005 and focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. He currently serves on the Boards of Atlas portfolio companies Bicycle, miRagen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail), Proprius (acquired by Cypress Biosciences), and Stromedix (acquired by Biogen Idec). Bruce was on the Board of Avila, which was acquired by Celgene in 2012.
Donald Morrissey Executive Director, SRS
Don leads the Life Sciences Practice for SRS. An accomplished business executive and attorney, Don brings 20 years experience in the life sciences sector. Previously, Don helped grow two venture-backed start-up companies through initial public offerings. He has been responsible for many strategic transactions involving licensing, partnering and M&A, as well as financings with leading venture capital and private equity firms.
Kingsley Taft Partner, Goodwin Procter
Kingsley is national co-chair of Goodwin Procter's Life Sciences Practice. He represents biotech, pharma and medtech companies in all aspects of their business and legal affairs, ranging from private financings, M&A and capital markets transactions, to strategic alliances and collaborations. Kingsley represents buyers and sellers in complex M&A and is particularly skilled in negotiating structured transactions.